Song Wenpeng, Liu Huan, Su Yingying, Zhao Qian, Wang Xiaoyan, Cheng Pengfei, Wang Hao
Department of Stomatology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
Beijing Laboratory of Oral Health, School of Basic Medicine, School of Stomatology, Capital Medical University, Beijing, China.
Front Cell Dev Biol. 2024 Jan 19;12:1346996. doi: 10.3389/fcell.2024.1346996. eCollection 2024.
Salivary gland hypofunction (SGH) caused by systemic disease, drugs, aging, and radiotherapy for head and neck cancer can cause dry mouth, which increases the risk of disorders such as periodontitis, taste disorders, pain and burning sensations in the mouth, dental caries, and dramatically reduces the quality of life of patients. To date, the treatment of SGH is still aimed at relieving patients' clinical symptoms and improving their quality of life, and is not able to repair and regenerate the damaged salivary glands. Pluripotent stem cells (PSCs), including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), and extended pluripotent stem cells (EPSCs), are an emerging source of cellular therapies that are capable of unlimited proliferation and differentiation into cells of all three germ layers. In recent years, the immunomodulatory and tissue regenerative effects of PSCs, their derived cells, and paracrine products of these cells have received increasing attention and have demonstrated promising therapeutic effects in some preclinical studies targeting SGH. This review outlined the etiologies and available treatments for SGH. The existing efficacy and potential role of PSCs, their derived cells and paracrine products of these cells for SGH are summarized, with a focus on PSC-derived salivary gland stem/progenitor cells (SGS/PCs) and PSC-derived mesenchymal stem cells (MSCs). In this Review, we provide a conceptual outline of our current understanding of PSCs-based therapy and its importance in SGH treatment, which may inform and serve the design of future studies.
由全身性疾病、药物、衰老以及头颈部癌症放疗引起的唾液腺功能减退（SGH）可导致口干，这会增加患牙周炎、味觉障碍、口腔疼痛和烧灼感、龋齿等疾病的风险，并显著降低患者的生活质量。迄今为止，SGH的治疗仍旨在缓解患者的临床症状并改善其生活质量，而无法修复和再生受损的唾液腺。多能干细胞（PSC），包括胚胎干细胞（ESC）、诱导多能干细胞（iPSC）和扩展多能干细胞（EPSC），是一种新兴的细胞治疗来源，能够无限增殖并分化为所有三个胚层的细胞。近年来，PSC及其衍生细胞以及这些细胞的旁分泌产物的免疫调节和组织再生作用受到越来越多的关注，并在一些针对SGH的临床前研究中显示出有前景的治疗效果。本综述概述了SGH的病因和可用治疗方法。总结了PSC及其衍生细胞以及这些细胞的旁分泌产物对SGH的现有疗效和潜在作用，重点关注PSC衍生的唾液腺干/祖细胞（SGS/PC）和PSC衍生的间充质干细胞（MSC）。在本综述中，我们提供了对基于PSC的治疗及其在SGH治疗中的重要性的当前理解的概念性概述，这可能为未来研究的设计提供参考并发挥作用。
